NO20013641L - BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser - Google Patents

BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser

Info

Publication number: NO20013641L
Authority: NO; Norway
Prior art keywords: baff; immunoglobulins; stimulating; inhibiting; cells
Prior art date: 1999-01-25

Application number

NO20013641A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013641D0 (no

Inventor

Jeffrey Browning

Christine Ambrose

Fabienne Mackay

Jurg Tschopp

Pascal Schneider

Original Assignee

Apotech Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-25

Filing date

2001-07-24

Publication date

2001-09-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26815006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013641(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-07-24 Application filed by Apotech Sa filed Critical Apotech Sa

2001-07-24 Publication of NO20013641D0 publication Critical patent/NO20013641D0/no

2001-09-25 Publication of NO20013641L publication Critical patent/NO20013641L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Environmental Sciences (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Husbandry (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biodiversity & Conservation Biology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Cardiology (AREA)
Virology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Oncology (AREA)

NO20013641A 1999-01-25 2001-07-24 BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser NO20013641L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11716999P	1999-01-25	1999-01-25
US14322899P	1999-07-09	1999-07-09
PCT/US2000/001788 WO2000043032A2 (fr)	1999-01-25	2000-01-25	Baff, agents bloquants associes et utilisation de ceux-ci pour stimuler et inhiber la reponse immunitaire des lymphocytes b et des immunoglobulines

Publications (2)

Publication Number	Publication Date
NO20013641D0 NO20013641D0 (no)	2001-07-24
NO20013641L true NO20013641L (no)	2001-09-25

Family

ID=26815006

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20013641A NO20013641L (no)	1999-01-25	2001-07-24	BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser
NO20120524A NO20120524A1 (no)	1999-01-25	2012-04-27	Anvendelse av BAFF-relaterte antistoff for fremstilling av medikamenter mot lymfoproliferative sykdommer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20120524A NO20120524A1 (no)	1999-01-25	2012-04-27	Anvendelse av BAFF-relaterte antistoff for fremstilling av medikamenter mot lymfoproliferative sykdommer

Country Status (29)

Country	Link
US (1)	US6869605B2 (fr)
EP (5)	EP1146892B1 (fr)
JP (5)	JP5066314B2 (fr)
KR (1)	KR100834809B1 (fr)
CN (1)	CN100340292C (fr)
AT (2)	ATE247482T1 (fr)
AU (1)	AU762839B2 (fr)
BR (1)	BR0007719A (fr)
CA (1)	CA2360062A1 (fr)
CY (2)	CY1107453T1 (fr)
CZ (1)	CZ299819B6 (fr)
DE (1)	DE60004635T2 (fr)
DK (2)	DK1146892T3 (fr)
EA (1)	EA006108B1 (fr)
EE (1)	EE05699B1 (fr)
ES (1)	ES2204528T3 (fr)
HK (1)	HK1040628B (fr)
HU (1)	HUP0105283A3 (fr)
IL (3)	IL144202A0 (fr)
IS (1)	IS5993A (fr)
MX (1)	MXPA01007464A (fr)
NO (2)	NO20013641L (fr)
NZ (1)	NZ513284A (fr)
PL (1)	PL198934B1 (fr)
PT (2)	PT1146892E (fr)
SI (1)	SI1146892T1 (fr)
SK (1)	SK286665B6 (fr)
TR (2)	TR200102147T2 (fr)
WO (1)	WO2000043032A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US6689579B1 (en)	1996-10-25	2004-02-10	Human Genome Sciences, Inc.	Polynucleotides encoding neutrokine-α
US20030175208A1 (en) *	1996-10-25	2003-09-18	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
US8212004B2 (en) *	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
EP0878552A1 (fr)	1997-05-13	1998-11-18	Erasmus Universiteit Rotterdam	Détection moléculaire d'aberration chromosomique
CA2327542C (fr)	1998-05-04	2011-11-22	Dako A/S	Procede et sondes de detection d'aberrations chromosomiques
GB9828628D0 (en)	1998-12-23	1999-02-17	Glaxo Group Ltd	Novel ligand
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
WO2002094852A2 (fr)	2001-05-24	2002-11-28	Zymogenetics, Inc.	Proteines hybrides taci-immunoglobuline
CA2360062A1 (fr) *	1999-01-25	2000-07-27	Biogen, Inc.	Baff, agents bloquants associes et utilisation de ceux-ci pour stimuler et inhiber la reponse immunitaire des lymphocytes b et des immunoglobulines
US20050100548A1 (en) *	2001-07-24	2005-05-12	Biogen Idec Ma Inc.	BAFF, inhibitors thereof and their use in the modulation of B-cell response
US20030095967A1 (en) *	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
AU4986700A (en)	1999-05-06	2000-11-21	National Jewish Medical And Research Center	Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
SK288603B6 (sk)	1999-08-17	2018-10-01	Biogen Ma Inc.	Polypeptid a protilátka viažuca sa na polypeptid
UA74798C2 (uk)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU2048501A (en) *	2000-02-16	2001-08-27	Genentech Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
EP2281843B1 (fr)	2000-06-16	2016-10-12	Human Genome Sciences, Inc.	Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte B (BLyS)
US7879328B2 (en) *	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en)	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001288301A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
AU2001285066B2 (en) *	2000-08-18	2006-06-29	Human Genome Sciences, Inc.	Binding polypeptides for B lymphocyte stimulator protein (BLYS)
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
PL393317A1 (pl)	2001-05-11	2011-05-23	Amgen Inc.	Peptydy oraz pokrewne cząsteczki wiążące TALL-1
HUP0500992A3 (en) *	2001-08-03	2007-11-28	Genentech Inc	Tacis and br3 polypeptides and uses thereof
AR035119A1 (es)	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
WO2003035846A2 (fr) *	2001-10-24	2003-05-01	National Jewish Medical And Research Center	Structures tridimensionnelles de tall-1 et de ses recepteurs parents, proteines modifiees et procedes associes
US20080267965A1 (en) *	2002-02-21	2008-10-30	Kalled Susan L	Use of Bcma as an Immunoregulatory Agent
JP2005533863A (ja) *	2002-07-25	2005-11-10	ジェネンテック・インコーポレーテッド	Ｔａｃｉ抗体とその用途
EP1558640B1 (fr)	2002-10-29	2011-04-13	Anaphore, Inc.	Proteines de liaison trimeriques destinees a des cytokines trimeriques
US7553930B2 (en)	2003-01-06	2009-06-30	Xencor, Inc.	BAFF variants and methods thereof
WO2004074511A1 (fr) *	2003-02-21	2004-09-02	Garvan Institute Of Medical Research	Diagnostic et traitement des maladies auto-immunes mediees par baff et du cancer
AU2004220078A1 (en) *	2003-03-07	2004-09-23	Xencor, Inc	BAFF mutants with at least one amino acid substitution and methods of their production
CA2520097C (fr)	2003-03-28	2014-10-07	Biogen Idec Ma Inc.	Recepteurs baff tronques
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
PL1631313T3 (pl) *	2003-06-05	2015-08-31	Genentech Inc	Terapia skojarzona zaburzeń z komórek B
EP1675609A1 (fr)	2003-10-20	2006-07-05	Biogen Idec MA Inc.	Regimes therapeutiques pour antagonistes baff
AU2004315198A1 (en)	2004-01-29	2005-08-18	Genentech, Inc.	Variants of the extracellular domain of BCMA and uses thereof
EP1826218B1 (fr) *	2004-08-31	2014-01-01	Kowa Company, Ltd.	Anticorps anti-baff humain
NZ583905A (en)	2004-10-13	2011-12-22	Univ Washington	Use of BAFF to Treat Sepsis
CA2596537A1 (fr) *	2005-01-28	2006-08-03	Apollo Life Sciences Limited	Molecules et leurs molecules chimeriques
DE602006007323D1 (de) *	2005-01-28	2009-07-30	Biogen Idec Inc	VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
MX2007014463A (es) *	2005-05-18	2008-04-07	Biogen Idec Inc	Metodos para tratar condiciones fibroticas.
KR20080056714A (ko)	2005-08-09	2008-06-23	지모제넥틱스, 인코포레이티드	ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
CA2618763A1 (fr)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
JP5905184B2 (ja) *	2005-10-13	2016-04-20	ヒューマンジノームサイエンシーズ，インコーポレイテッドＨｕｍａｎＧｅｎｏｍｅＳｃｉｅｎｃｅｓ，Ｉｎｃ．	自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
WO2007062090A2 (fr)	2005-11-23	2007-05-31	Genentech, Inc.	Procedes et compositions lies a des analyses de lymphocytes b
WO2007123765A2 (fr)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
JP2009537563A (ja)	2006-05-15	2009-10-29	アレストレーディングソシエテアノニム	Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
WO2010093993A2 (fr) *	2009-02-12	2010-08-19	Human Genome Sciences, Inc.	Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
KR101717809B1 (ko) *	2010-03-11	2017-03-17	질레드 코네티컷 인코포레이티드	이미다조피리딘 ｓｙｋ 억제제
WO2013171296A1 (fr)	2012-05-16	2013-11-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Diagnostic et traitement de la sarcoïdose
CZ304104B6 (cs) *	2012-08-22	2013-10-23	Masarykova Univerzita	B-bunecný aktivující faktor pro zvýsení sliznicní imunity kojencu a prípravek jej obsahující
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
US9688767B2 (en)	2013-03-15	2017-06-27	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
KR101493592B1 (ko)	2013-04-29	2015-02-17	부산대학교 산학협력단	Ｓｏｃｓ3 단백질을 이용한 ｂａｆｆ 연관 면역질환 치료제 스크리닝 방법
JP6505689B2 (ja)	2013-11-19	2019-04-24	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	ヒト化ｂ細胞活性化因子遺伝子を有する非ヒト動物
TWI735853B (zh)	2013-12-23	2021-08-11	美商克洛諾斯生技有限公司	脾酪胺酸激酶抑制劑
WO2015100246A1 (fr)	2013-12-24	2015-07-02	Ossianix, Inc.	Composés à liaison sélective baff et procédés associés
AU2015315834B2 (en)	2014-01-31	2019-12-12	Boehringer Ingelheim International Gmbh	Novel anti-BAFF antibodies
AR104368A1 (es)	2015-04-03	2017-07-19	Lilly Co Eli	Anticuerpos biespecíficos anti-cd20- / anti-baff
EP3313429B1 (fr)	2015-06-19	2021-10-06	University Of Louisville Research Foundation, Inc.	Immunomodulation pour la prévention et le traitement à long terme de maladies auto-immunes et du rejet de tissu étranger
CN107328620B (zh) *	2017-06-23	2020-06-05	浙江普罗亭健康科技有限公司	用于流式细胞技术的封闭缓冲液及试剂盒
WO2019126366A2 (fr) *	2017-12-19	2019-06-27	The Johns Hopkins University	Thérapie anti-baff pour favoriser l'immunité antitumorale
WO2019210168A1 (fr) *	2018-04-26	2019-10-31	University Of Virginia Patent Foundation	Compositions et méthodes de traitement d'un anévrisme aortique abdominal
AU2020225455A1 (en)	2019-02-22	2021-09-09	Kronos Bio, Inc.	Solid forms of condensed pyrazines as Syk inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en)	1988-12-20	1993-01-05	Baylor College Of Medicine	Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en)	1989-06-05	1993-10-26	Gilead Sciences, Inc.	Exonuclease-resistant oligonucleotides
US5264564A (en)	1989-10-24	1993-11-23	Gilead Sciences	Oligonucleotide analogs with novel linkages
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US6541224B2 (en)	1996-03-14	2003-04-01	Human Genome Sciences, Inc.	Tumor necrosis factor delta polypeptides
WO1997033902A1 (fr)	1996-03-14	1997-09-18	Human Genome Sciences, Inc.	Facteurs de necrose tumorale delta et epsilon chez l'homme
PT939804E (pt) *	1996-10-25	2005-11-30	Human Genome Sciences Inc	Neutroquina alfa
SE505941C2 (sv)	1996-10-29	1997-10-27	Bjoern Hellstroem	Klämskyddslist
AU5705898A (en) *	1996-12-17	1998-07-15	Schering Corporation	Mammalian cell surface antigens; related reagents
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (fr) *	1997-04-02	1998-10-02	Smithkline Beecham Corporation	Tl5, homologue tnf
IL133315A0 (en) *	1997-06-06	2001-04-30	Regeneron Pharma	Ntn-2 member of tnf ligand family
CA2292835A1 (fr)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
AU9376498A (en)	1997-09-05	1999-03-22	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
HUP0004034A3 (en)	1997-09-12	2002-08-28	Apotech R & D Sa	Kay - a novel immune system protein
CA2303615A1 (fr)	1997-09-12	1999-03-18	Jurg Tschopp	Nouveaux ligands de la famille des tnf
JP2002503444A (ja)	1997-11-26	2002-02-05	イーライ・リリー・アンド・カンパニー	リガンドファミリー遺伝子
US6297367B1 (en)	1997-12-30	2001-10-02	Chiron Corporation	Polynucleotide encoding TNFL1
WO1999033980A2 (fr)	1997-12-30	1999-07-08	Chiron Corporation	Membres de familles de tnf et de tnfr
WO2000026244A2 (fr)	1998-11-04	2000-05-11	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nouveau membre de la famille des facteurs de necrose des tumeurs, ligand du recepteur de la mort cellulaire (drl) et compositions et procedes correspondants
GB9828628D0 (en)	1998-12-23	1999-02-17	Glaxo Group Ltd	Novel ligand
DE60005135T3 (de)	1999-01-07	2015-04-09	Zymogenetics, Inc.	Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung
CA2360062A1 (fr) *	1999-01-25	2000-07-27	Biogen, Inc.	Baff, agents bloquants associes et utilisation de ceux-ci pour stimuler et inhiber la reponse immunitaire des lymphocytes b et des immunoglobulines
US6475986B1 (en)	1999-02-02	2002-11-05	Research Development Foundation	Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en)	1999-02-23	2004-05-28	Human Genome Sciences Inc	Neutrokine-alpha and neutrokine-alpha splice variant
EP1157126A4 (fr)	1999-02-24	2005-03-02	Gen Hospital Corp	Procede de clonage de produits intermediaires de transduction de signaux
AU4986700A (en)	1999-05-06	2000-11-21	National Jewish Medical And Research Center	Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
NZ520789A (en) *	2000-02-11	2005-01-28	Biogen Inc	Heterologous polypeptide of the TNF family
EP2281843B1 (fr)	2000-06-16	2016-10-12	Human Genome Sciences, Inc.	Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte B (BLyS)
CA2419661A1 (fr)	2000-08-15	2002-03-07	Guo-Liang Yu	Neutrokine-alpha et variant d'epissage de neutrokine-alpha
EP1456347A4 (fr)	2001-11-16	2006-08-02	Human Genome Sciences Inc	Anticorps se liant a blys selon un mode immunospecifique

2000
- 2000-01-25 CA CA002360062A patent/CA2360062A1/fr not_active Abandoned
- 2000-01-25 DE DE60004635T patent/DE60004635T2/de not_active Expired - Fee Related
- 2000-01-25 JP JP2000594485A patent/JP5066314B2/ja not_active Expired - Lifetime
- 2000-01-25 BR BR0007719-4A patent/BR0007719A/pt not_active Application Discontinuation
- 2000-01-25 SI SI200030207T patent/SI1146892T1/xx unknown
- 2000-01-25 PL PL349772A patent/PL198934B1/pl unknown
- 2000-01-25 DK DK00909970T patent/DK1146892T3/da active
- 2000-01-25 NZ NZ513284A patent/NZ513284A/en not_active IP Right Cessation
- 2000-01-25 AT AT00909970T patent/ATE247482T1/de active
- 2000-01-25 EP EP00909970A patent/EP1146892B1/fr not_active Revoked
- 2000-01-25 EP EP10181337A patent/EP2319527A3/fr not_active Ceased
- 2000-01-25 TR TR2001/02147T patent/TR200102147T2/xx unknown
- 2000-01-25 EP EP15174329.1A patent/EP2974736A1/fr not_active Withdrawn
- 2000-01-25 EP EP10180420.1A patent/EP2298332B1/fr not_active Expired - Lifetime
- 2000-01-25 AU AU32142/00A patent/AU762839B2/en not_active Expired
- 2000-01-25 SK SK1044-2001A patent/SK286665B6/sk not_active IP Right Cessation
- 2000-01-25 WO PCT/US2000/001788 patent/WO2000043032A2/fr not_active Ceased
- 2000-01-25 AT AT03018879T patent/ATE515267T1/de active
- 2000-01-25 EP EP03018879A patent/EP1415659B9/fr not_active Revoked
- 2000-01-25 CZ CZ20012696A patent/CZ299819B6/cs not_active IP Right Cessation
- 2000-01-25 HK HK02102203.7A patent/HK1040628B/en not_active IP Right Cessation
- 2000-01-25 PT PT00909970T patent/PT1146892E/pt unknown
- 2000-01-25 MX MXPA01007464A patent/MXPA01007464A/es active IP Right Grant
- 2000-01-25 IL IL14420200A patent/IL144202A0/xx unknown
- 2000-01-25 HU HU0105283A patent/HUP0105283A3/hu unknown
- 2000-01-25 CN CNB008054878A patent/CN100340292C/zh not_active Expired - Lifetime
- 2000-01-25 DK DK03018879.1T patent/DK1415659T3/da active
- 2000-01-25 PT PT03018879T patent/PT1415659E/pt unknown
- 2000-01-25 KR KR1020017009356A patent/KR100834809B1/ko not_active Expired - Lifetime
- 2000-01-25 EE EEP200100386A patent/EE05699B1/xx unknown
- 2000-01-25 EA EA200100822A patent/EA006108B1/ru not_active IP Right Cessation
- 2000-01-25 ES ES00909970T patent/ES2204528T3/es not_active Expired - Lifetime
2001
- 2001-01-25 TR TR2004/03498T patent/TR200403498T2/xx unknown
- 2001-07-06 IS IS5993A patent/IS5993A/is unknown
- 2001-07-09 IL IL144202A patent/IL144202A/en not_active IP Right Cessation
- 2001-07-24 NO NO20013641A patent/NO20013641L/no not_active Application Discontinuation
- 2001-07-24 US US09/911,777 patent/US6869605B2/en not_active Expired - Fee Related
2003
- 2003-11-14 CY CY20031101083T patent/CY1107453T1/el unknown
2008
- 2008-11-27 JP JP2008303135A patent/JP4955642B2/ja not_active Expired - Fee Related
2009
- 2009-08-20 IL IL200498A patent/IL200498A0/en unknown
2011
- 2011-10-05 CY CY20111100946T patent/CY1112458T1/el unknown
2012
- 2012-01-24 JP JP2012012379A patent/JP2012087145A/ja not_active Withdrawn
- 2012-03-29 JP JP2012077812A patent/JP2012126749A/ja active Pending
- 2012-04-27 NO NO20120524A patent/NO20120524A1/no not_active Application Discontinuation
2014
- 2014-04-24 JP JP2014090152A patent/JP2014141527A/ja active Pending

Also Published As

Publication number	Publication date
NO20120524A1 (no)	2012-04-27
IL144202A (en)	2010-04-29
TR200102147T2 (tr)	2002-04-22
CY1107453T1 (el)	2012-05-23
SK286665B6 (sk)	2009-03-05
EP1146892B1 (fr)	2003-08-20
PL349772A1 (en)	2002-09-09
WO2000043032A2 (fr)	2000-07-27
EE200100386A (et)	2002-12-16
DE60004635T2 (de)	2004-06-09
TR200403498T2 (tr)	2005-03-21
EE05699B1 (et)	2014-02-17
KR20010105331A (ko)	2001-11-28
JP4955642B2 (ja)	2012-06-20
JP2014141527A (ja)	2014-08-07
ES2204528T3 (es)	2004-05-01
CZ20012696A3 (cs)	2001-10-17
US20020037852A1 (en)	2002-03-28
HK1040628B (en)	2005-10-14
DK1415659T3 (da)	2011-10-03
SI1146892T1 (en)	2004-02-29
AU762839B2 (en)	2003-07-03
ATE247482T1 (de)	2003-09-15
DE60004635D1 (de)	2003-09-25
MXPA01007464A (es)	2003-06-06
EA006108B1 (ru)	2005-08-25
PL198934B1 (pl)	2008-08-29
EP1415659B1 (fr)	2011-07-06
EP2319527A3 (fr)	2011-10-12
CY1112458T1 (el)	2015-12-09
HUP0105283A2 (hu)	2002-04-29
DK1146892T3 (da)	2003-11-24
EP2974736A1 (fr)	2016-01-20
PT1146892E (pt)	2003-12-31
US6869605B2 (en)	2005-03-22
ATE515267T1 (de)	2011-07-15
CN1347326A (zh)	2002-05-01
EP2298332A1 (fr)	2011-03-23
KR100834809B1 (ko)	2008-06-05
IS5993A (is)	2001-07-06
CZ299819B6 (cs)	2008-12-03
JP5066314B2 (ja)	2012-11-07
JP2009102326A (ja)	2009-05-14
EA200100822A1 (ru)	2002-02-28
PT1415659E (pt)	2011-10-13
JP2002535285A (ja)	2002-10-22
WO2000043032A3 (fr)	2000-12-14
AU3214200A (en)	2000-08-07
EP1415659B9 (fr)	2012-02-15
IL200498A0 (en)	2011-07-31
SK10442001A3 (sk)	2002-02-05
BR0007719A (pt)	2001-11-13
EP1146892A2 (fr)	2001-10-24
CA2360062A1 (fr)	2000-07-27
JP2012126749A (ja)	2012-07-05
CN100340292C (zh)	2007-10-03
NZ513284A (en)	2003-10-31
HUP0105283A3 (en)	2004-08-30
IL144202A0 (en)	2002-05-23
EP2319527A2 (fr)	2011-05-11
JP2012087145A (ja)	2012-05-10
EP2298332B1 (fr)	2015-07-08
NO20013641D0 (no)	2001-07-24
HK1065724A1 (en)	2005-03-04
EP1415659A1 (fr)	2004-05-06
HK1040628A1 (en)	2002-06-21

Publication	Publication Date	Title
NO20013641L (no)	2001-09-25	BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser
AU2002366641A1 (en)	2003-06-23	Methods for inhibiting ocular processes
BG108214A (en)	2004-09-30	Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
IL172646A0 (en)	2006-04-10	Antibodies against interleukin -22 and uses therefor
TR200001312T2 (tr)	2000-09-21	Benzotiyazol protein tirozin kinaz önleyicileri.
WO2000022143A3 (fr)	2000-09-28	Homologues de proteines kinases
WO2000029574A3 (fr)	2000-10-05	Genes associes a des inflammations
EA200400235A1 (ru)	2004-10-28	Комбинированная терапия для лечения рака
WO2000018922A3 (fr)	2000-10-26	Proteines humaines associees a des glucides
WO1999049038A3 (fr)	2000-02-10	Proteines de fixation du calcium humaines
WO2000078953A3 (fr)	2002-01-17	Proteines de transport humaines
WO2000000594A3 (fr)	2000-06-29	Transferases humaines
WO2001044448A3 (fr)	2002-01-17	Proteines d'oxydoreductase humaines
WO1999031128A3 (fr)	1999-10-07	Proteines du type facteur humain de necrose tumorale r2
WO1999041373A3 (fr)	1999-12-16	Molecules humaines associees au transport
WO1999038981A3 (fr)	1999-11-18	Molecules de proteine kinase humaines
DE69534753D1 (de)	2006-04-06	Nierenpolycystose-gen
WO2000065054A3 (fr)	2001-02-15	Proteines humaines associees aux membranes
TR200100240T2 (tr)	2002-01-21	Anksiyete bozukluklarının tedavisi
WO2000077040A3 (fr)	2001-04-26	Molecules de signalisation intracellulaires
WO2000001821A3 (fr)	2000-06-15	Proteines associees a la neurotransmission
WO2000008155A3 (fr)	2000-06-29	Proteines associees a un recepteur humain
WO1999038976A3 (fr)	1999-11-25	Homologues de facteurs de croissance humains
WO2000024911A3 (fr)	2000-08-10	Phospholipases humaines
WO1999041375A3 (fr)	1999-12-16	Proteines receptrices humaines

Legal Events

Date	Code	Title	Description
2014-02-10	FC2A	Withdrawal, rejection or dismissal of laid open patent application